

Fig. 3. HCV propagation in FLC4 cells cultured in the RFB system following inoculation with pooled sera obtained from HCV carriers. The 3D-cultured FLC4 cells were incubated with a pooled serum sample for 12 h, followed by changing the culture medium to fresh one. Culture medium was periodically collected for 42 days after inoculation, and HCV RNA and the viral core protein were quantified, respectively, by real-time RT-PCR and ELISA. (A) HCV RNA level in culture supernatant. (B) HCV-core protein (closed circles) and oxygen consumption (open triangles) levels in culture supernatant. (C) Changes in the viral quasispecies distribution after the inoculation. Percentages in the inoculum or in the culture medium at each time point (day 3, 9, 19, or 33 p.i.) are indicated at the right side. *, termination codon.

mL RFB column, as estimated from the glucose consumption (Kawada et al., 1998). Culture medium in the RFB was replaced with fresh medium 12 h post-infection (p.i.) and periodically sampled for 42 days.

Fig. 3A and B shows the levels of HCV RNA and viral core protein in the culture medium, respectively. HCV RNA was not observed on the first 2 days following infection, but was detectable from day 3 p.i. Viral RNA levels fluctuated, with peaks on days 3, 9, 19–21 and 33–36 p.i. At days 19–21 p.i., the average amount of HCV RNA detected in the culture supernatant was approximately 3×10^6 copies/day. Intermittent peaks were observed in HCV core protein levels in the culture supernatant, and the peak pattern of the core protein was largely consistent with that of viral RNA. During the infection experiment, the level of oxygen consumption was constant at approximately 12 ppm, thus suggesting that the desired conditions (constant or very gradually increasing cell number) were maintained.

3.3. Quasispecies analysis in RFB culture

The above results suggest that, although the environment was consistent in the pooled serum infection, there were periods in which the viruses actively replicated and released from the cells and periods in which they poorly replicated. The pooled serum used for the infection exhibited HCV populations had at least 26 distinct quasispecies (Table 1). To investigate whether the quasispecies distribution was altered due to infection, and whether HCV populations are selected during long-term culture in the RFB, total RNA was extracted from the culture supernatant samples collected on days 3, 9, 19 and 33 p.i., and the nucleotide sequence of the region containing HVR1 was deter-

mined, as described above. As shown in Fig. 3C, it is of interest that only two HCV species were detected in the sample at day 3 p.i.; the dominant clone C1-1, comprising approximately 70% of the viral population, and clone B4, comprising 30%. Although clone C1-1 was not detected in the sequence of the inoculum shown in Table 1, it was most similar to clone C1, a dominant clone in plasma C, among the HCV population observed in the inoculum; thus, it is possible that clone C1-1 is one of the minor species in serum C. Clone B4 was found to be derived from serum B. An almost identical HCV population was observed in the sample at day 9 p.i. In this sample, the dominant clone C1-1 and clone B4-1, which differs from clone B4 by only one amino acid, were detected. In contrast, more significant variation in quasispecies structure of the HCV species was observed in the sample at day 19 p.i. than that at day 9 p.i. With B4 as the dominant clone, the serum B-derived HCV species, clones B4 and B4-2, which differs from clone B4 by one amino acid, comprised 58% of the total population. Four types of HCV sequences derived from serum C were detected. Two of these (clones C1-3 and C1-4) contained lethal mutations. It was also found that the HCV species detected in the sample at day 33 p.i. included only two clones (clones B4 and B4-3), derived from serum B. The dominant clone, B4, was found to comprise 89% of the total population.

3.4. Potential use of the RFB system for evaluation of anti-HCV compounds

An experiment was carried out to determine whether this HCV infection experiment system was useful for the evaluation of anti-HCV drugs (Fig. 4). For this purpose, a small,




Fig. 4. A therapeutic effect of IFN in HCV infection model in the RFB cultures. HCV-infected FLC4 cells were treated with or without 100 IU/mL IFN- α . (A) Culture media were periodically collected, and HCV RNA levels were determined. Closed circles: without IFN treatment, open circles: treatment with IFN. (B) Changes in the viral quasispecies distribution in the cells without IFN treatment. Percentages in the inoculum or in the culture medium on day 32 p.i. are indicated at the right side. *, termination codon.

4-mL RFB column was adopted and a pair of RFB cultures infected with the HCV-positive pooled plasma (Table 1) was prepared. IFN- α was added to one culture at a final concentration of 100 IU/mL at 12 h p.i. No cytotoxicity was observed in FLC4 cells under these conditions (data not shown). Culture media from two cultures (12.5 mL each) were sampled periodically for 35 days and replaced by the same volume of fresh medium in the presence or absence of IFN- α . HCV RNA in the collected media was quantified by real-time RT-PCR, as described above. As shown in Fig. 4A, in the no-treatment culture, fluctuations in the viral RNA levels with the peaks on days 7, 18, and 32 p.i. (1.5 – 5×10^4 copies/mL) were observed. However, while HCV RNA at 0.5 – 0.8×10^4 copies/mL was detected in the IFN-treated culture at days 5–11 p.i., no HCV RNA was detected at days 12–30 p.i. Serum levels of hepatic transaminases such as ALT and AST are known to be markers of liver damage. In the HCV-infection model with FLC4 cells cultured in RFB, the AST levels in the culture medium, which ranged from 5 to 10 IU/L without HCV infection, increased to 20–50 IU/L according to the viral infection (data not shown). Such increased AST levels were found to fall by the IFN treatment to lower than 10 IU/L at day 28 p.i. As reported previously, the ALT levels in the culture medium were constantly low; its levels were less than 10 IU/mL, with or without HCV infection (Aizaki et al., 2003). The viral nucleotide sequence in the no-treatment culture medium at day 32 p.i. was determined. It was found that serum B-derived clone B4 was dominant, and serum C-derived clone C1 was present as a minor clone (Fig. 4B); thus, the results corresponded well with those demonstrated in Fig. 3. An increase in viral RNA in the IFN-treated culture after day 32 p.i. was observed; although the degree of increase was only slight (Fig. 4A). It will be interesting to test whether HCV species grown in the IFN-treated culture is a variant resistant to IFN- α .

4. Discussion

At present an important limitation of the *in vitro* HCV infection system is that the only established culture system is based on genotype 2a, JFH-1 isolate, and Huh-7-derived cell lines. The development of alternate infection systems in which other HCV strains and host cells are available has been needed for the study of HCV dynamics and virus–host interactions, and for testing antivirals. This paper demonstrates that a long-term culture of the 3D RFB system is a useful tool for investigating HCV dynamics. The present results revealed that the viral quasispecies distribution altered in the HCV infection system in the RFB system. The change probably occurs in the following two-stage process. The first change was observed on day 3 p.i.; thus, it is possible that the HCV species were selected according to infectivity in FLC4 cells. It has been reported that HCV particle populations in chronic hepatitis C patients consist of low-density virions and higher-density immune complex forms (Hijikata et al., 1993; Kanto et al., 1994). Inoculation of cultured cells with HCV has demonstrated that the immune complex forms were less infective than the antibody-unbound virions (Shimizu et al., 1994). Therefore, another hypothesis may be that a large number of HCV populations in sera A, D, E, and F are immune complex forms; thus, these sera are less susceptible to the cells than sera B and C. The second change was observed on days 19–33 p.i. While the serum C-derived clone was dominant in the early stages after infection, the serum B-derived HCV clone became dominant over time. In the absence of immunological selection pressure, viral nucleotide mutations at random positions are accumulated during viral replication, and the newly generated variant species are selected principally, if not solely, based on the intrinsic replicative advantages or disadvantages that these mutations confer. Thus, these results suggest that the use of pooled serum sample allowed for screening of infectious materials compatible for the RFB culture.

Evaluation methods for anti-HCV drugs using monolayer culture systems with various culture cells, such as the replicon system and the JFH-1 based virion production system, have been reported (Bartenschlager et al., 2003; Blight et al., 2000; Boriskin et al., 2006; Lanford et al., 2003; Lindenbach et al., 2005; Lohmann et al., 1999; Wakita et al., 2005; Zhong et al., 2005). These methods utilize viral markers, such as HCV RNA and antigens, as indicators of treatment efficacy. However, the utility of long-term cell culture systems for anti-HCV drug evaluation based on infection with human sera is still limited. The use of a chimpanzee model, the only non-human host for HCV infection, is restricted due to several reasons such as problematic availability and ethical consideration. Given intensive efforts to reduce and replace animal testing in the course of development of new therapies worldwide, the RFB-based HCV infection model is a potential alternative to animal models such chimpanzee for assessing anti-HCV compounds. According to the studies with regards to mathematical modeling of HCV kinetics (Dahari et al., 2005; Dixit et al., 2004; Layden et al., 2003; Layden-Almer et al., 2006; Perelson et al., 2005), IFN therapy against HCV infection generally generates a biphasic decline in viral load; there is a rapid decrease in the serum HCV RNA level over the

first 1 day of treatment, followed by the second phase, which is slower than the first-phase viral decline. To date, there were no such observable viral kinetics in the IFN treatment under such experimental settings. Further detailed kinetic analyses of the use of varying doses of IFN and of very early time points to evaluate the antiviral effect are in progress.

In summary, by investigating the dynamics of HCV populations in the RFB culture system, it was demonstrated that HCV was intermittently detected in the culture supernatants of long-term culture, and that changes in viral quasispecies appear to be related to this fluctuation in the virus level. It was also shown that an HCV-infection model using the RFB system is useful for evaluating potential antivirals. Further investigation on the infection and growth of various HCV-positive sera is currently being conducted in order to obtain an adaptive clone with higher replication efficiency in this culture system.

Acknowledgements

The authors thank T. Wakita and S. Nagamori for helpful discussion and suggestions. We also thank M. Matsuda, T. Shimoji and M. Yahata for technical assistance, and T. Mizoguchi for secretarial work. This work was supported in part by a grant for Research on Health Sciences focusing on Drug Innovation from the Japan Health Sciences Foundation; by grants-in-aid from the Ministry of Health, Labor and Welfare; and by the program for Promotion of Fundamental Studies in Health Sciences of the National Institute of Biomedical Innovation, Japan.

References

- Aizaki, H., Aoki, Y., Harada, T., Ishii, K., Suzuki, T., Nagamori, S., Toda, G., Matsuura, Y., Miyamura, T., 1998. Full-length complementary DNA of hepatitis C virus genome from an infectious blood sample. *Hepatology* 27, 621–627.
- Aizaki, H., Nagamori, S., Matsuda, M., Kawakami, H., Hashimoto, O., Ishiko, H., Kawada, M., Matsuura, T., Hasumura, S., Matsuura, Y., Suzuki, T., Miyamura, T., 2003. Production and release of infectious hepatitis C virus from human liver cell cultures in the three-dimensional radial-flow bioreactor. *Virology* 314, 16–25.
- Aoki, Y., Aizaki, H., Shimoike, T., Tani, H., Ishii, K., Saito, I., Matsuura, Y., Miyamura, T., 1998. A human liver cell line exhibits efficient translation of HCV RNAs produced by a recombinant adenovirus expressing T7 RNA polymerase. *Virology* 250, 140–150.
- Bartenschlager, R., Kaul, A., Sparacio, S., 2003. Replication of the hepatitis C virus in cell culture. *Antivir. Res.* 60, 91–102.
- Blight, K.J., Kolykhalov, A.A., Rice, C.M., 2000. Efficient initiation of HCV RNA replication in cell culture. *Science* 290, 1972–1974.
- Boriskin, Y.S., Pecheur, E.I., Polyak, S.J., 2006. Arbidol: a broad-spectrum antiviral that inhibits acute and chronic HCV infection. *Viol. J.* 3, 56.
- Choo, Q.L., Kuo, G., Weiner, A.J., Overby, L.R., Bradley, D.W., Houghton, M., 1989. Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* 244, 359–362.
- Choo, Q.L., Richman, K.H., Han, J.H., Berger, K., Lee, C., Dong, C., Gallegos, C., Coit, D., Medina-Selby, R., Barr, P.J., et al., 1991. Genetic organization and diversity of the hepatitis C virus. *Proc. Natl. Acad. Sci. U.S.A.* 88, 2451–2455.
- Dahari, H., Major, M., Zhang, X., Mihalik, K., Rice, C.M., Perelson, A.S., Feinstone, S.M., Neumann, A.U., 2005. Mathematical modeling of primary hepatitis C infection: noncytolytic clearance and early blockage of virion production. *Gastroenterology* 128, 1056–1066.
- Dixit, N.M., Layden-Almer, J.E., Layden, T.J., Perelson, A.S., 2004. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. *Nature* 432, 922–924.
- Grakoui, A., McCourt, D.W., Wychowski, C., Feinstone, S.M., Rice, C.M., 1993. Characterization of the hepatitis C virus-encoded serine proteinase: determination of proteinase-dependent polyprotein cleavage sites. *J. Virol.* 67, 2832–2843.
- Hijikata, M., Kato, N., Ootsuyama, Y., Nakagawa, M., Shimotohno, K., 1991. Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. *Proc. Natl. Acad. Sci. U.S.A.* 88, 5547–5551.
- Hijikata, M., Shimizu, Y.K., Kato, H., Iwamoto, A., Shih, J.W., Alter, H.J., Purcell, R.H., Yoshikura, H., 1993. Equilibrium centrifugation studies of hepatitis C virus: evidence for circulating immune complexes. *J. Virol.* 67, 1953–1958.
- Hongo, T., Kajikawa, M., Ishida, S., Ozawa, S., Ohno, Y., Sawada, J., Umezawa, A., Ishikawa, Y., Kobayashi, T., Honda, H., 2005. Three-dimensional high-density culture of HepG2 cells in a 5-ml radial-flow bioreactor for construction of artificial liver. *J. Biosci. Bioeng.* 99, 237–244.
- Ikedo, M., Sugiyama, K., Mizutani, T., Tanaka, T., Tanaka, K., Sekihara, H., Shimotohno, K., Kato, N., 1998. Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus. *Virus Res.* 56, 157–167.
- Iwahori, T., Matsuura, T., Maehashi, H., Sugo, K., Saito, M., Hosokawa, M., Chiba, K., Masaki, T., Aizaki, H., Ohkawa, K., Suzuki, T., 2003. CYP3A4 inducible model for in vitro analysis of human drug metabolism using a bioartificial liver. *Hepatology* 37, 665–673.
- Kanto, T., Hayashi, N., Takehara, T., Hagiwara, H., Mita, E., Naito, M., Kasahara, A., Fusamoto, H., Kamada, T., 1994. Buoyant density of hepatitis C virus recovered from infected hosts: two different features in sucrose equilibrium density-gradient centrifugation related to degree of liver inflammation. *Hepatology* 19, 296–302.
- Kawada, M., Nagamori, S., Aizaki, H., Fukaya, K., Niiya, M., Matsuura, T., Sujino, H., Hasumura, S., Yashida, H., Mizutani, S., Ikenaga, H., 1998. Massive culture of human liver cancer cells in a newly developed radial flow bioreactor system: ultrafine structure of functionally enhanced hepatocarcinoma cell lines. *In Vitro Cell Dev. Biol. Anim.* 34, 109–115.
- Kuo, G., Choo, Q.L., Alter, H.J., Gitnick, G.L., Redeker, A.G., Purcell, R.H., Miyamura, T., Dienstag, J.L., Alter, M.J., Stevens, C.E., et al., 1989. An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. *Science* 244, 362–364.
- Lanford, R.E., Guerra, B., Lee, H., Averett, D.R., Pfeiffer, B., Chavez, D., Notvall, L., Bigger, C., 2003. Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. *J. Virol.* 77, 1092–1104.
- Layden, T.J., Layden, J.E., Ribeiro, R.M., Perelson, A.S., 2003. Mathematical modeling of viral kinetics: a tool to understand and optimize therapy. *Clin. Liver Dis.* 7, 163–178.
- Layden-Almer, J.E., Cotler, S.J., Layden, T.J., 2006. Viral kinetics in the treatment of chronic hepatitis C. *J. Viral Hepat.* 13, 499–504.
- Lindenbach, B.D., Evans, M.J., Syder, A.J., Wolk, B., Tellinghuisen, T.L., Liu, C.C., Maruyama, T., Hynes, R.O., Burton, D.R., McKeating, J.A., Rice, C.M., 2005. Complete replication of hepatitis C virus in cell culture. *Science* 309, 623–626.
- Lohmann, V., Korner, F., Koch, J., Herian, U., Theilmann, L., Bartenschlager, R., 1999. Replication of subgenomic hepatitis C virus RNAs in a hepatoma cell line. *Science* 285, 110–113.
- Martell, M., Esteban, J.I., Quer, J., Genesca, J., Weiner, A., Esteban, R., Guardia, J., Gomez, J., 1992. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. *J. Virol.* 66, 3225–3229.
- Murakami, K., Ishii, K., Ishihara, Y., Yoshizaki, S., Tanaka, K., Gotoh, Y., Aizaki, H., Kohara, M., Yoshioka, H., Mori, Y., Manabe, N., Shoji, I., Sata, T., Bartenschlager, R., Matsuura, Y., Miyamura, T., Suzuki, T., 2006. Production of infectious hepatitis C virus particles in three-dimensional cultures of the cell line carrying the genome-length dicistronic viral RNA of genotype 1b. *Virology* 351, 381–392.

- Pawlotsky, J.M., 2006. Hepatitis C virus population dynamics during infection. *Curr. Top. Microbiol. Immunol.* 299, 261–284.
- Perelson, A.S., Herrmann, E., Micol, F., Zeuzem, S., 2005. New kinetic models for the hepatitis C virus. *Hepatology* 42, 749–754.
- Poynard, T., Yuen, M.F., Ratziu, V., Lai, C.L., 2003. Viral hepatitis C. *Lancet* 362, 2095–2100.
- Saito, I., Miyamura, T., Ohbayashi, A., Harada, H., Katayama, T., Kikuchi, S., Watanabe, Y., Koi, S., Onji, M., Ohta, Y., et al., 1990. Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. *Proc. Natl. Acad. Sci. U.S.A.* 87, 6547–6549.
- Shimizu, Y.K., Hijikata, M., Iwamoto, A., Alter, H.J., Purcell, R.H., Yoshikura, H., 1994. Neutralizing antibodies against hepatitis C virus and the emergence of neutralization escape mutant viruses. *J. Virol.* 68, 1494–1500.
- Suzuki, T., Omata, K., Satoh, T., Miyasaka, T., Arai, C., Maeda, M., Matsuno, T., Miyamura, T., 2005. Quantitative detection of hepatitis C virus (HCV) RNA in saliva and gingival crevicular fluid of HCV-infected patients. *J. Clin. Microbiol.* 43, 4413–4417.
- Tagawa, M., Kato, N., Yokosuka, O., Ishikawa, T., Ohto, M., Omata, M., 1995. Infection of human hepatocyte cell lines with hepatitis C virus in vitro. *J. Gastroenterol. Hepatol.* 10, 523–527.
- Wakita, T., Pietschmann, T., Kato, T., Date, T., Miyamoto, M., Zhao, Z., Murthy, K., Habermann, A., Krausslich, H.G., Mizokami, M., Bartenschlager, R., Liang, T.J., 2005. Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. *Nat. Med.* 11, 791–796.
- Zhong, J., Gastaminza, P., Cheng, G., Kapadia, S., Kato, T., Burton, D.R., Wieland, S.F., Uprichard, S.L., Wakita, T., Chisari, F.V., 2005. Robust hepatitis C virus infection in vitro. *Proc. Natl. Acad. Sci. U.S.A.* 102, 9294–9299.

Limited suppression of the interferon- β production by hepatitis C virus serine protease in cultured human hepatocytes

Hiromichi Dansako, Masanori Ikeda and Nobuyuki Kato

Department of Molecular Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Japan

Keywords

antiviral response; hepatitis C virus; innate immune response; interferon- β ; serine protease

Correspondence

N. Kato, Department of Molecular Biology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1 Shikata-cho, Okayama 700-8558, Japan
Fax: +81 86 2357392
Tel: +81 86 2357385
E-mail: nkato@md.okayama-u.ac.jp

(Received 14 February 2007, revised 10 June 2007, accepted 15 June 2007)

doi:10.1111/j.1742-4658.2007.05942.x

Toll-like receptors and RNA helicase family members [retinoic acid-inducible gene I (RIG-I) and melanoma differentiation associated gene-5 (MDA5)] play important roles in the induction of interferon- β as a major event in innate immune responses after virus infection. TRIF (adaptor protein of Toll-like receptor 3)-mediated and Cardif (adaptor protein of RIG-I or MDA5)-mediated signaling pathways contribute rapid induction of interferon- β through the activation of interferon regulatory factor-3 (IRF-3). Previously, it has been reported that the hepatitis C virus NS3-4A serine protease blocks virus-induced activation of IRF-3 in the human hepatoma cell line HuH-7, and that NS3-4A cleaves TRIF and Cardif molecules, resulting in the interruption of antiviral signaling pathways. On the other hand, it has recently been reported that non-neoplastic human hepatocyte PH5CH8 cells retain robust TRIF- and Cardif-mediated pathways, unlike HuH-7 cells, which lack a TRIF-mediated pathway. In the present study, we further investigated the effect of NS3-4A on antiviral signaling pathways. Although we confirmed that PH5CH8 cells were much more effective than HuH-7 cells for the induction of interferon- β , we obtained the unexpected result that NS3-4A could not suppress the interferon- β production induced by the TRIF-mediated pathway, although it suppressed the Cardif-mediated pathway by cleaving Cardif at the Cys508 residue. Using PH5CH8, HeLa, and HuH-7-derived cells, we further showed that NS3-4A could not cleave TRIF, in disagreement with a previous report describing the cleavage of TRIF by NS3-4A. Taken together, our findings suggest that the blocking of the interferon production by NS3-4A is not sufficient in HCV-infected hepatocyte cells.

Persistent infection by hepatitis C virus (HCV) frequently causes chronic hepatitis [1,2], which progresses to liver cirrhosis and hepatocellular carcinoma [3,4]. This is a serious health problem because approximately 170 million people are currently infected with HCV worldwide [5]. To resolve the mechanism of persistent HCV infection, it will be necessary to better under-

stand the virus life cycle and then to develop more effective anti-HCV reagents. HCV is an enveloped positive ssRNA (9.6 kb) virus belonging to the *Flaviviridae* family [6,7]. The HCV genome encodes a large poly-protein precursor of approximately 3000 amino acid residues, which is cleaved co- and post-translationally into at least ten proteins in the order: core, envelope 1

Abbreviations

CARD, caspase recruitment domain; E1, envelope 1; EGFP, enhanced green fluorescent protein; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; HCV, hepatitis C virus; HEK293, human embryonic kidney 293; IFN, interferon; IRF-3, interferon regulatory factor 3; IKK- ϵ , inhibitor of κ B kinase ϵ ; MDA5, melanoma differentiation associated gene-5; MyD88, myeloid differentiation factor 88; NS2, nonstructural protein 2; RIG-I, retinoic acid-inducible gene I; siRNA, small interfering RNA; TBK, Tank-binding kinase 1; TLR, Toll-like receptor; TRIF, Toll-IL1 receptor domain-containing adaptor inducing IFN- β .

(E1), E2, p7, nonstructural protein 2 (NS2), NS3, NS4A, NS4B, NS5A, and NS5B. These cleavages are mediated by the host and virally encoded serine protease located in the amino-terminal domain of NS3. Serine protease activity of NS3 requires NS4A, a protein consisting of 54 amino acid residues, to form a stable complex with the NS3 [8–10].

Virus-infected cells trigger the innate immune response by recognizing viral components, including DNA, ssRNA, dsRNA and glycoproteins. This response initiates signaling pathways leading to the induction of protective cellular genes, including type-I interferons [initially interferon (IFN)- β , and then IFN- α] and proinflammatory cytokines that directly limit viral replication. Within these signaling pathways, Toll-like receptors (TLRs) and RNA helicase family members play very important roles in the recognition of the viral components [11,12].

IFN- β is induced by dsRNA, a common intermediate in many RNA virus infections, including HCV. The viral dsRNA as well as the synthetic dsRNA analogue poly(I-C) are recognized by TLR3, which is expressed on the cell surface or in endosome vesicles [13,14]. On the other hand, it has been shown that retinoic acid-induced gene I (RIG-I) and melanoma differentiation-associated gene 5 (MDA5) also recognize dsRNA molecules [15–17]. A recent study showed that MDA5 and RIG-I recognize different types of dsRNA: MDA5 recognizes poly(I-C), and RIG-I recognizes *in vitro* transcribed dsRNA [18]. Very recently, it was discovered that viral 5'-triphosphate RNA is the ligand for RIG-I [19,20]. Both MDA5 and RIG-I contain DexD/H-box helicase domains that serve as intracellular cytoplasmic dsRNA and 5'-triphosphate RNA receptors, respectively [15–20]. After dsRNA is recognized, the cytoplasmic domain of TLR3 recruits TIR-domain-containing adaptor inducing IFN- β (TRIF) through a myeloid differentiation factor 88 (MyD88)-independent pathway (TRIF-mediated pathway) [21–23]. In contrast, the caspase recruitment domains (CARDs) of MDA5 or RIG-I recruit the CARD adaptor inducing IFN- β , Cardif (also known as IPS-1, MAVS, or VISA), which was recently identified as an adaptor protein located in the outer membrane of mitochondria (this recruitment is known as the Cardif-mediated pathway) [24–27].

The TRIF- and Cardif-mediated signaling pathways rapidly induce IFN- β through the phosphorylation of multiple cellular factors, including IFN regulatory factor-3 (IRF-3) and kinases, including the Tank-binding kinase 1 (TBK-1) and inhibitor of κ B kinase ϵ (IKK- ϵ) [28–31]. Although IRF-3 is located in the cytoplasm in an inactive state [28,29], phosphorylation (Ser385, 386,

396, 398, 402, 405, and Thr404) of IRF-3 by TBK-1 and IKK- ϵ induces dimerization and nuclear translocation of IRF-3, leading to transcriptional activation of IFN- β [28–31].

Recent studies have found that several RNA virus proteins could inhibit the early signaling activation (TRIF- and Cardif-mediated pathways) leading to IFN- β production [32,33]. Regarding HCV, Foy *et al.* [33] found that NS3-4A serine protease blocked HCV-induced activation of IRF-3 in the human hepatoma cell line HuH-7. Additional studies regarding this finding have shown that NS3-4A blocks the Cardif-mediated signaling pathway by cleaving the Cardif molecule and blocking downstream IFN- β activation [24,34,35], and that TBK-1, IKK- ϵ , and TRIF may also be targeted for cleaving by NS3-4A [36–38]. With respect to TRIF, NS3-4A was reported to cleave this molecule in both an *in vitro* experiment using a reticulocyte lysate system and an *in vivo* experiment using human embryonic kidney 293 (HEK293) and UNS3-4A-24 osteosarcoma cells [36]. These studies suggest that NS3-4A has the ability to inhibit both TRIF- and Cardif-mediated signaling pathways.

On the other hand, we recently demonstrated that HCV proteins exhibited conflicting effects on the IFN- β production in non-neoplastic human hepatocyte PH5CH8 cells [39,40]: Core and NS5B synergistically enhanced IFN- β expression and this enhancement was dependent on the RNA-dependent RNA polymerase activity of NS5B, but NS3-4A significantly inhibited the production of IFN- β induced by the combination of Core and NS5B. Furthermore, Li *et al.* [41] recently reported that PH5CH8 cells retained robust and functionally active TRIF- and Cardif-mediated signaling pathways, unlike HuH-7 cells, which lacked the TRIF-mediated pathway [41,42]. Therefore, using poly(I-C) as an inducer of IFN- β , we investigated the effects of NS3-4A on antiviral signaling pathways in PH5CH8 cells. Our results showed that the extracellular TLR3/TRIF signaling pathway was not blocked by NS3-4A because NS3-4A did not cleave TRIF, unlike in the previous study [36].

Results

Human hepatocyte PH5CH8 cells more readily activate IFN- β transcription in response to dsRNA compared to HuH-7 cells and their sublines

Recently, Li *et al.* [41] reported that PH5CH8 cells showed a better response to dsRNA, including IFN- β induction, than other human hepatoma cell lines (HuH-7, HepG2, and Hep3B). Therefore, using a dual

luciferase reporter assay, we first confirmed that PH5CH8 cells were much more effective at inducing IFN- β than HuH-7 cells and HuH-7-derived cell sublines (O [43], Oc [43], and OR6c [44]) that can support HCV RNA replication.

When the dsRNA analog, poly(I-C), was transfected into cells using a liposome-mediated procedure (intracellular dsRNA, T-pIC), PH5CH8 cells showed a more potent (> 25-fold) activation of the IFN- β gene promoter than HuH-7 and HuH-7-derived cell lines (Fig. 1A). Furthermore, when poly(I-C) was added to the culture medium (extracellular dsRNA; M-pIC), a

significant elevation (12-fold) of the IFN- β gene promoter was observed in PH5CH8 cells only (Fig. 1B). These results were confirmed by quantitative RT-PCR analysis of endogenous IFN- β mRNA induction in cells treated with poly(I-C) (T-pIC, Fig. 1C; M-pIC, Fig. 1D). In both T-pIC and M-pIC treatments, the induction level of IFN- β mRNA was markedly higher in PH5CH8 cells than in O, Oc, OR6c, and HuH-7 cells (Fig. 1C,D). Next, we carried out quantitative RT-PCR analysis of TLR3, TRIF, RIG-I, MDA5, Cardif, and IRF-3 mRNAs to clarify their expression levels in the steady state and the effects of poly(I-C)




Fig. 1. PH5CH8 cells show high-level IFN- β production in response to dsRNA. (A) Dual luciferase reporter assay of the IFN- β gene promoter using the various cells treated with T-pIC. The following HuH-7-derived cell sublines were used: O, cloned cells [43] replicating genome-length HCV RNA; Oc, cured cells which were created by eliminating genome-length HCV RNA from the O cells by IFN treatment; and OR6c, cured cells which were created by eliminating genome-length HCV RNA from the cloned OR6 cells [44] by IFN treatment. Cells grown in 24-well plates were cotransfected with pIFN- β (-125)-Luc and pRL-CMV (internal control reporter) and cultured for 42 h, and then poly(I-C) (1 μ g) was transfected into the cells for 6 h before the reporter assay as described in the Experimental procedures. The relative luciferase activity was normalized to the activity of *Renilla* luciferase (internal control). The lysate of cells without poly(I-C) treatment was used as a control. Data are the means \pm SD from three independent experiments, each performed in triplicate. (B) Dual luciferase reporter assay of the IFN- β gene promoter using the various cells treated with M-pIC. The dual luciferase reporter assay was performed as described in (A) except that poly(I-C) was added to the medium (50 μ g mL $^{-1}$) for 6 h before the reporter assay. (C) Quantitative RT-PCR analysis of IFN- β mRNA in various cells treated with T-pIC. Poly(I-C) (1 μ g) was transfected into the cells for 6 h before the sampling for RNA preparation. Total RNA extracted from the cells was subjected to real-time LightCycler PCR analysis using the primer set of IFN- β (202 bp). Data are the means \pm SD from three independent experiments. To correct the differences in RNA quality and quantity between the samples, data were normalized using the ratio of IFN- β mRNA concentration to that of GAPDH. The IFN- β mRNA levels were calculated relative to the level in the O cells treated with T-pIC, which was set at 1.0. (D) Quantitative RT-PCR analysis of IFN- β mRNA in various cells treated with M-pIC. Poly(I-C) was added to the medium (50 μ g mL $^{-1}$) for 6 h before the sampling for RNA preparation. Quantitative RT-PCR analysis for IFN- β mRNA was performed as described in (C). The IFN- β mRNA level was calculated relative to the level in the O cells treated with M-pIC, which was set at 1.0.

treatment (T-pIC and M-pIC). In T-pIC treatment, RIG-I and MDA5 mRNAs were clearly induced in PH5CH8 and HuH-7 cells, and TLR3 mRNA was induced only in PH5CH8 cells. Moreover, there was no such induction in the other cell lines examined (supplementary Table S1). In M-pIC treatment, TLR3, RIG-I, and MDA5 were induced only in PH5CH8 cells (supplementary Table S1). The fact that these mRNAs were induced at substantial levels only in PH5CH8 cells treated with T-pIC or M-pIC suggests that the elevation of these mRNAs is mediated by the IFN- β induced by poly(I-C) treatment. In summary, these results revealed that PH5CH8 cells retain both the Cardif- and TRIF-mediated pathways for IFN- β production, whereas HuH-7 cells retain only the Cardif-mediated pathway, and that the HuH-7-derived cell lines used are lacking in both pathways for IFN- β production.

Parental PH5CH and PH5CH clones other than PH5CH8 also exhibit IFN- β response toward poly(I-C) treatment

PH5CH8 is one of eight cell lines that were previously cloned from parental PH5CH cells to examine HCV susceptibility *in vitro* [45]. Therefore, we used a dual luciferase assay to examine the effects of poly(I-C) treatment on the IFN- β gene promoter in PH5CH cells and these cloned cell lines. When T-pIC treatment was employed, the parental cells and all the cloned cell lines exhibited good IFN- β response, and the activation level in PH5CH2 and PH5CH6 cells was higher than that in PH5CH8 cells (Fig. 2A). However, when M-pIC treatment was used, the IFN- β response in the cloned cells and the parental cells was less than 50% of that in PH5CH8 cells (Fig. 2B). From these results, we concluded that PH5CH8 is the best cell line for the study of the dsRNA-induced antiviral signaling pathways.

M-pIC treatment activates IRF-3 through the TLR3/TRIF signaling pathway

To confirm that the TRIF-mediated pathway is activated in M-pIC treatment, and to determine if its activation is mediated by the TLR3 but not the TLR4 signaling pathway, we examined whether or not activation of IRF-3 by M-pIC treatment is specifically mediated by the TLR3 signaling pathway using TLR3-, TLR4-, and TRIF-specific small interfering RNA (siRNAs) [46,47]. Quantitative RT-PCR analysis revealed that the TLR3, TLR4, and TRIF mRNAs were drastically decreased (more than 70% reduction) in the




Fig. 2. IFN- β responses of parental PH5CH and PH5CH cloned cells by dsRNA treatment. (A) Dual luciferase reporter assay of the IFN- β gene promoter using parental PH5CH and PH5CH cloned cells treated with T-pIC. The T-pIC treatment and the dual luciferase reporter assay were performed as described in Fig. 1A. The IFN- β gene promoter activity level was calculated relative to the level in the PH5CH8 cells, which was set at 100. (B) Dual luciferase reporter assay of the IFN- β gene promoter using parental PH5CH and PH5CH cloned cells treated with M-pIC. The M-pIC treatment and the dual luciferase reporter assay were performed as described in Fig. 1B. The relative level of the IFN- β gene promoter activity was calculated as described in (A).

PH5CH8 cells transfected with TLR3, TLR4, and TRIF siRNAs, respectively, but not in the PH5CH8 cells transfected with the GL2 siRNA used as a control (Fig. 3A). We also confirmed that IRF-3 mRNA was not decreased in PH5CH8 cells transfected with any of these siRNAs (Fig. 3A). Under this condition, we performed a luciferase reporter assay using an IFN- β gene promoter in PH5CH8 cells treated with M-pIC. The activation of the IFN- β gene promoter was greatly suppressed (by more than 80%) in PH5CH8 cells transfected with TLR3 or TRIF siRNA, but not in the PH5CH8 cells transfected with GL2 or TLR4 siRNA (Fig. 3B). This result suggests that the activation of IRF-3 by M-pIC treatment is mediated by the TLR3/TRIF signaling pathway. We obtained further evidence by examining the status of the phosphorylation and dimerization of IRF-3. The results




Fig. 3. Extracellular dsRNA treatment activates IRF-3 through the TLR3/TRIF signaling pathway in PH5CH8 cells. (A) Down-regulation of TLR3, TLR4, and TRIF mRNAs by transfection of TLR3, TLR4, and TRIF siRNAs, respectively. PH5CH8 cells were transfected with dsRNA duplexes targeting TLR3, TLR4, TRIF or luciferase GL2. After 3 days, the expression levels of TLR3, TLR4, TRIF, and IRF-3 mRNAs were determined by the quantitative RT-PCR as described previously [67]. (B) Dual luciferase reporter assay of the IFN- β gene promoter using siRNA-transfected PH5CH8 cells treated with M-pIC. The poly(I-C) treatment and the dual luciferase reporter assay were performed as described in Fig. 1. (C) Phosphorylation and dimerization analyses of IRF-3 in the siRNA-transfected PH5CH8 cells treated with poly(I-C). The poly(I-C) treatment was performed as described in Fig. 1. The lysate of cells transfected with GL2, TLR3, TLR4, or TRIF siRNA was prepared, and subjected to Native-PAGE as described in the Experimental procedures. The phosphorylation and dimerization of IRF-3 were analyzed by immunoblotting using anti-phospho-IRF-3 (Ser386) serum and anti-IRF-3 serum, respectively.

obtained by M-pIC treatment revealed that both the phosphorylation and dimerization of IRF-3 were almost completely abrogated in the cells transfected with TLR3 or TRIF siRNA, but not in those transfected with the GL2 and TLR4 siRNAs (Fig. 3C, right panel). Such a suppression of IRF-3 activation was not observed by T-pIC treatment (Fig. 3C, left panel), suggesting that the activation of IRF-3 by T-pIC treatment is mainly mediated by the Cardif-mediated signaling pathway [16].

HCV NS3-4A blocks the Cardif-mediated signaling pathway, but not the TRIF-mediated signaling pathway

Several studies [24,33,36,48–50] have demonstrated that NS3-4A blocks IFN- β induction by inhibiting the

nuclear translocation of IRF-3 in HuH-7 cells harboring HCV replicons and HCV (JFH1 strain of genotype 2a)-infected HuH-7 cells. However, it has also been reported that HuH-7 cells possess weak or defective dsRNA-induced antiviral signaling pathways [41,42] (Fig. 1). Therefore, we examined whether or not NS3-4A can block the induction of IFN- β by poly(I-C) in PH5CH8 cells that retain dsRNA-induced signaling pathways. The results were quite different between T-pIC treatment and M-pIC treatment. First, in T-pIC treatment, the results showed that NS3-4As (the 1B-1 and HCV-O strains of genotype 1b) could drastically inhibit the enhancement of the IFN- β gene promoter activity, and that this suppressive effect of NS3-4A was dependent on its serine protease activity, because the NS3-4A/S1165A mutant lacking the serine protease activity did not exhibit the suppressive effect,




Fig. 4. NS3-4A blocked the Cardif-mediated signaling pathway, but not the TRIF-mediated signaling pathway. The poly(I:C) treatment, dual luciferase reporter assay, and quantitative RT-PCR analysis were performed as described in Fig. 1. The pCX4bsr expression vectors encoding NS3-4A, NS3, or NS4A from the 1B-1 strain and NS3-4A from the HCV-O strain were used for the transfection. The pCX4bsr expression vector encoding the NS3-4A/S1165A mutant (1B-1 strain) lacking serine protease activity or the NS3-4A/W1528A mutant (1B-1 strain) lacking RNA helicase activity was also used for the transfection. The lysate of PH5CH8 cells transfected with the pCX4bsr vector was used as a control (NS-). (A) Effect of NS3-4A on the IFN-β gene promoter activated by T-pIC treatment. (B) Effect of NS3-4A on the IFN-β gene promoter activated by M-pIC treatment. (C) Effect of NS3-4A on the IFN-β mRNA induction by T-pIC treatment. PH5CH8 cells stably expressing the NS3-4A or NS3-4A mutant (S1165A or W1528A) from the 1B-1 strain were subjected to T-pIC treatment. PH5CH8 cells infected with pCX4bsr retrovirus were used as a control (NS-). The IFN-β mRNA level was calculated relative to the level in the control PH5CH8 cells treated with T-pIC, which was set at 100. (D) Effect of NS3-4A on the IFN-β mRNA induction by M-pIC treatment. PH5CH8 cells that were the same as in (C) were subjected to M-pIC treatment. The IFN-β mRNA level was calculated relative to the level in the control PH5CH8 cells treated with M-pIC, which was set at 100.

although the NS3-4A/W1528A mutant lacking RNA helicase activity did (Fig. 4A). In addition, we confirmed that NS3 alone or NS4A alone did not exhibit the suppressive effect, but coexpression of NS3 and NS4A did, suggesting that the NS3/4A complex *in trans* [51] also can block IFN-β induction. In M-pIC treatment, however, we found that NS3-4As (strains 1B-1 and O) could not suppress the induction of the IFN-β gene promoter (Fig. 4B). Similar results

were also obtained in the other cloned cell lines, PH5CH3 and PH5CH6 (data not shown), and in HeLa cells (supplementary Fig. S1). The results of the reporter assay were confirmed by quantitative RT-PCR analysis of endogenous IFN-β mRNA induced by T-pIC or M-pIC treatment in PH5CH8 cells. We found that the NS3-4A and NS3-4A/W1528A mutants, but not the NS3-4A/S1165A mutant, could suppress the induction of IFN-β mRNA following

T-pIC treatment (Fig. 4C), but none of these NS3-4As could suppress the induction of IFN- β mRNA following M-pIC treatment (Fig. 4D).

We next examined the effects of NS3-4A on the phosphorylation and dimerization of IRF-3 in PH5CH8 cells. We observed that both T-pIC and M-pIC treatments induced the phosphorylation at Ser386 and Ser396 of IRF-3, and formed the dimerization of IRF-3 (Fig. 5A,B, lanes 1 and 2), and that NS3-4A remarkably inhibited the phosphorylation and dimerization of IRF-3 in the cells treated with T-pIC, depending on its protease activity (Fig. 5A). However, the phosphorylation and dimerization of IRF-3 induced by M-pIC treatment was not inhibited by NS3-4A (Fig. 5B). From these results, we concluded that, in PH5CH8 cells, NS3-4A could not block the

TRIF-mediated signaling pathway, although it could block the Cardif-mediated signaling pathway.

NS3-4A blocks the Cardif-mediated pathway by cleaving Cardif

NS3-4A is able to cleave the Cardif [24,34,35] and TRIF [36] molecules, resulting in the blocking of dsRNA-induced antiviral signaling pathways. However, our finding that IFN- β production was not suppressed by NS3-4A in cells treated with M-pIC seemed to contradict the finding of a previous study [36] in which NS3-4A-mediated cleavage of TRIF inhibited dsRNA-activated signaling through the TLR3 pathway. Therefore, we evaluated whether or not NS3-4A could impair the functional ability of





Fig. 5. Effect of NS3-4A on phosphorylation and dimerization of IRF-3 in PH5CH8 cells treated with intracellular or extracellular dsRNA. PH5CH8 cells that were the same as in Fig. 4C were used. The poly(I-C) treatment was performed as described in Fig. 1. (A) Effect of NS3-4A on phosphorylation and dimerization of IRF-3 in the PH5CH8 cells treated with T-pIC. The phosphorylation and dimerization analyses of IRF-3 were performed as described in Fig. 3C. Anti-phospho-IRF-3 (Ser396) serum was also used for the analysis. (B) Effects of NS3-4A on phosphorylation and dimerization of IRF-3 in the PH5CH8 cells treated with M-pIC. The phosphorylation and dimerization analyses of IRF-3 were performed as described in (A).



TRIF as well as Cardif in PH5CH8 cells. First, we confirmed the effect of NS3-4A on the activation of the IFN- β gene promoter by the Cardif exogenously expressed in PH5CH8 cells. The results of the luciferase reporter assay revealed that NS3-4As (strains 1B-1 and HCV-O) completely suppressed the activation (200-fold induction) of the IFN- β gene promoter by Cardif, and that this suppression was dependent on the serine protease activity of NS3-4A (Fig. 6A). This result was supported by the results of the dimerization analysis of IRF-3 (Fig. 6B). Next, we confirmed that wild-type Cardif, but not the Cardif mutant (C508A located in the C-terminal region), was cleaved by the NS3-4As (strains 1B-1 and HCV-O), and that this cleavage was dependent on its serine protease activity (Fig. 6C). These results are in agreement with previous studies in which NS3-4A blocked the intracellular dsRNA signaling pathways through cleavage at the Cys508 residue of Cardif [24,34,35].

Fig. 6. NS3-4A blocks Cardif-mediated pathways by cleaving Cardif. (A) Effect of NS3-4A on the IFN- β gene promoter activated by the ectopic expression of Cardif in PH5CH8 cells. PH5CH8 cells were cotransfected with the pCX4bsr expression vector encoding NS3-4A or its mutant S1165A or W1528A, as described in Fig. 4, and the pCX4pur expression vector encoding myc-Cardif. The lysate of PH5CH8 cells transfected with the pCX4bsr and pCX4pur vectors was used as a control (NS-). The dual luciferase reporter assay was performed as described in Fig. 1A. (B) Effect of NS3-4A on IRF-3 dimerization induced by the ectopic expression of Cardif in PH5CH8 cells. The enhanced green fluorescent protein (EGFP)-IRF3 expression vector was used for the cotransfection in PH5CH8 cells with the myc-Cardif and NS3-4A (wild-type or its mutant S1165A or W1528A) expression vectors. The lysate of PH5CH8 cells transfected with the pCX4bsr and pCX4pur vectors was used as a control (NS-). The dimerization analysis of IRF-3 was performed as described in Fig. 3C using anti-EGFP serum. (C) Cardif is cleaved by NS3-4A in PH5CH8 cells. PH5CH8 cells were cotransfected with the myc-Cardif (wild-type or its mutant C508A) and NS3-4A expression vectors (wild-type or its mutant S1165A or W1528A). Production of the myc-Cardif and NS3 in these cells was analyzed by immunoblotting using anti-myc and anti-NS3 sera, respectively. The PH5CH8 cells transfected with the pCX4bsr and pCX4pur vectors were used as a control (NS-). β -actin was used as a control for the amount of protein loaded per lane. The black and white arrowheads indicate Cardif and the cleaved Cardif, respectively.

NS3-4A does not block the TRIF-mediated pathway because it lacks the ability to cleave TRIF

Because we demonstrated that NS3-4A blocked the intracellular dsRNA signaling pathways through cleavage of Cardif in PH5CH8 cells, we performed the same analysis regarding TRIF exogenously expressed in PH5CH8 cells. The results of the luciferase reporter assay using the IFN- β gene promoter revealed that NS3-4As (strains 1B-1 and HCV-O) could not suppress the activation (1000-fold induction) of the IFN- β gene promoter by TRIF (Fig. 7A). This result was also supported by the results of the dimerization analysis of IRF-3 (Fig. 7B). Furthermore, we demonstrated that the exogenously expressed TRIF was not cleaved by NS3-4As (strains 1B-1 and HCV-O) (Fig. 7C). These results indicate that NS3-4A could not block the TRIF-mediated signaling pathway, and suggest that NS3-4A did not suppress the M-pIC-induced production of IFN- β because NS3-4A did not have the ability to cleave TRIF.

To confirm the results obtained in PH5CH8 cells, we examined the status of Cardif and TRIF molecules expressed exogenously in the O cells replicating genome-length HCV-O RNA efficiently and their cured Oc cells. The results revealed that Cardif was cleaved in the O cells but not in the Oc cells (Fig. 8A,B), and that the cleavage of Cardif occurred

when NS3-4As (strains 1B-1 and HCV-O) were expressed in the Oc cells (Fig. 8B). From these results, we confirmed that NS3-4A could cleave Cardif in the O and Oc cells. In contrast, TRIF was not cleaved in either O or Oc cells (Fig. 8C). We further confirmed that TRIF was not cleaved in the O cells transfected with TLR3 siRNA, indicating that the resistance of TRIF to NS3-4A is not related to the presence of TLR3 (Fig. 8C). We also performed the same analysis using HeLa cells, and obtained results (supplementary Fig. S2) similar to those obtained in PH5CH8 cells (Figs 6C, 7C and 8). In addition, we observed that, like TRIF, exogenously expressed MDA5 and RIG-I were not cleaved by NS3-4A in PH5CH8 cells (data not shown). Taken together, the above results indicate that NS3-4A cleaves the Cardif molecule, resulting in interruption of the Cardif-mediated pathway, but NS3-4A is not able to cleave the TRIF molecule, and thus the TRIF-mediated pathway is not suppressed by NS3-4A.


Discussion

In the present study, we demonstrated that parental PH5CH cells and their clones retained both TRIF- and Cardif-mediated pathways as antiviral dsRNA signaling pathways, and confirmed that the PH5CH8 cell line was far more useful for the study of antiviral pathways than HuH-7 or the cell lines cloned from it. From the results of the present study and a previous study [41], we considered the possibility that immortalized hepatocyte cells possess the functional TRIF- and Cardif-mediated signaling pathways. Based on this

assumption, we examined IFN- β production in three other immortalized human hepatocyte cell lines, NKNT-3 [52], IHH10.3 [53], and IHH12 [53], after treatment with poly(I-C). However, the results revealed that none of these immortalized cell lines responded to both M-pIC and T-pIC treatments. Therefore, we suggest that PH5CH and the cell lines cloned from it are uniquely suitable for the comprehensive study of antiviral TRIF- and Cardif-mediated signaling pathways.

We failed to obtain evidence that NS3-4A was able to cleave TRIF as reported by Li *et al.* [36]. In our study (Fig. 7C), there was no evidence of the cleavage of the TRIF molecule in NS3-4A-expressed PH5CH8

Fig. 7. NS3-4A does not block the TRIF-mediated pathway because it lacks the ability to cleave TRIF. (A) Effect of NS3-4A on the IFN- β gene promoter activated by the ectopic expression of TRIF in PH5CH8 cells. PH5CH8 cells were cotransfected with the pCX4bsr expression vector encoding NS3-4A or its mutant S1165A or W1528A, and the pCX4pur expression vector encoding myc-TRIF. The lysate of PH5CH8 cells transfected with the pCX4bsr and pCX4pur vectors was used as a control (NS-). The dual luciferase reporter assay was performed as described in Fig. 1A. (B) Effect of NS3-4A on IRF-3 dimerization induced by the ectopic expression of TRIF in PH5CH8 cells. The dimerization analysis of IRF-3 was performed as described in Fig. 6B except that the myc-TRIF expression vector was used in place of the myc-Cardif expression vector. (C) TRIF is not cleaved by NS3-4A in PH5CH8 cells. PH5CH8 cells were cotransfected with the myc-TRIF and NS3-4A (wild-type or its mutant S1165A or W1528A) expression vectors. Production of myc-TRIF and NS3 in these cells was analyzed by immunoblotting using anti-myc and anti-NS3 sera, respectively, as described in Fig. 6C. The black arrowhead indicates the noncleaved TRIF.






Fig. 8. TRIF is not cleaved in genome-length HCV RNA replicating cells. (A) Cardif is cleaved in the O cells replicating genome-length HCV-O RNA efficiently. The O cells were transfected with the myc-Cardif (wild-type or its mutant C508A) expression vector. Production of the myc-Cardif and NS3 in the O cells was analyzed by immunoblotting as described in Fig. 6C. The black and white arrowheads indicate Cardif and the cleaved Cardif, respectively. (B) Cardif is cleaved by NS3-4A in the cured Oc cells. The Oc cells were cotransfected with the myc-Cardif (wild-type or mutant C508A) and NS3-4A expression vectors. The production of the myc-Cardif and NS3 in these cells was analyzed by immunoblotting as described in Fig. 6C. The black and white arrowheads indicate Cardif and the cleaved Cardif, respectively. (C) TRIF is not cleaved in the O cells. The O and Oc cells were transfected with the myc-TRIF expression vector. The O cells transfected with GL2 or TLR3 siRNA were also used for the analysis. Production of myc-TRIF in these cells was analyzed by immunoblotting as described in Fig. 6C. The black arrowhead indicates the noncleaved TRIF.

HCV RNA replicating cells, and that NS3-4A was localized not only on the endoplasmic reticulum, but also on mitochondria [54]. From these findings, we suggest that NS3-4A is unable to cleave TRIF in cultured human cells.

Although amino acid sequences (PSSTPC/SAHLT, cleavage at Cys372; the P6 residue is underlined) surrounding the NS3-4A *trans*-cleavage site in TRIF [36] resemble those (DLEVVT/STWVL for NS3-4A; DEMEEC/ASHLP for NS4A/4B; DCSTPC/SGSWL for NS4B/5A; EDVVCC/SMSYS for NS5A/5B; the P6 residue is underlined) in the NS proteins from the 1B-1 and HCV-O strains and that (EREVPC/HRPSP, cleavage at Cys508; the P6 residue is underlined) in Cardif, only the TRIF site lacks the acidic P6 residue that is conserved and important in viral cleavage sites [55]. Accordingly, we examined whether or not a TRIF mutant (P to E at the P6 residue) is cleaved by NS3-4A in PH5CH8 cells. However, no cleavage of the TRIF mutant was observed (unpublished data). To clarify why TRIF is not cleaved by NS3-4A, further analysis will be necessary.

Although the results obtained in the present study suggest that the suppression of IFN- β production by NS3-4A is limited in human hepatocyte cells, it has recently been reported [56] that HCV can block the dsRNA-induced signaling pathway via the NS3-4A-independent pathway in addition to the NS3-4A-dependent pathway. However, because HuH-7 cells infected with the HCV genotype 2a clone (JFH1) were used in that study, it is not clear whether or not the TRIF-mediated pathway is also inhibited by the NS3-4A-independent pathway. To clarify this point, it will be necessary to study an HCV infection system using human hepatocyte cells in which both the TRIF- and

cells. Nor did we observe any cleavage of TRIF by the NS3-4A expressed in the Oc cells, which exhibited almost no response to the T-pIC and M-pIC treatments (Figs 1 and 8C), or the HeLa cells, which exhibited a good response to the T-pIC and M-pIC treatments (supplementary Figs S1 and S2). We further observed that TRIF was not cleaved in the O cells, in which the HCV NS protein precursor was efficiently processed by NS3-4A (Fig. 8C). Regarding the cellular localization of NS3-4A, it has recently been reported that the localization of NS3-4A expressed transiently in HuH-7 cells was the same as that in genome-length

Cardif-mediated pathways are functional, such as PH5CH8 cells.

We clearly demonstrated that Cardif was cleaved by NS3-4As of 1B-1 and HCV-O strains obtained from healthy HCV carriers [57]. Although we observed that this cleavage was dependent on the protease activity of NS3-4A (Fig. 6), the correlation between the inhibitory effect of NS3-4A on the Cardif-mediated signaling pathway and the protease activity of NS3-4A remains unclear. Furthermore, we have no evidence that all NS3-4As derived from patients with HCV are able to cleave the Cardif molecule. To clarify these issues, further comparative analysis among HCV strains obtained from patients with different hepatic disease conditions will be needed. In addition, in the present study, we observed that the bands corresponding to the cleaved Myc-Cardif became extremely intense in PH5CH8 cells (Fig. 6C). This phenomenon has been observed in previous studies [24,34,49]. Although these previous studies did not explain what caused this phenomenon, we speculate that the cleaved Myc-Cardif is transferred to the cytosolic (soluble) fraction, although noncleaved Myc-Cardif remains in the membrane (insoluble) fraction. To clarify the reason for this phenomenon, several experiments may be needed.

In summary, we show that NS3-4A could not cleave TRIF, but could cleave Cardif, in PH5CH8 cells possessing functional TRIF- and Cardif-mediated antiviral signaling pathways, and suggest that the disruption of the IFN- β production system by NS3-4A is not sufficient in HCV-infected hepatocyte cells. This information will be useful for understanding the roles of NS3-4A in persistent HCV infection.

Experimental procedures

Cell culture

Non-neoplastic human hepatocyte PH5CH-derived cloned cells, including PH5CH8 cells, which are susceptible to HCV infection and supportive of HCV replication [45], were maintained as described previously [58]. HuH-7 cells were cultured in Dulbecco's modified Eagle's medium (DMEM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum. The O cells replicating genome-length HCV RNA were cultured in DMEM with 10% fetal bovine serum and G418 ($300 \mu\text{g}\cdot\text{mL}^{-1}$; Geneticin, Invitrogen) as described previously [43]. The Oc and OR6c cured cells, which were created by eliminating genome-length HCV RNA from O cells [43] and OR6 cells [44] by IFN treatment, respectively, were also cultured in DMEM with 10% fetal bovine serum.

Construction of expression vectors

Retroviral vectors pCX4bsr and pCX4pur [59], which contain the resistance gene for blasticidin and puromycin, respectively, were used to construct the various expression vectors. pCX4bsr/NS3-4A(1B-1), pCX4bsr/NS3(1B-1) and pCX4bsr/NS4A(1B-1) were constructed according to the previously described method [60]. The DNA fragments encoding NS3-4A, NS3, and NS4A derived from the HCV 1B-1 strain belonging to genotype 1b (accession no. AB0802999) [61] were subcloned into the *EcoRI* and *NotI* sites of pCX4bsr. To construct pCX4bsr/NS3-4A(O), the DNA fragment encoding NS3-4A derived from the HCV-O strain belonging to genotype 1b [43] were also subcloned into the *EcoRI* and *NotI* sites of pCX4bsr. pCX4bsr/NS3-4A(1B-1)/S1165A and pCX4bsr/NS3-4A(1B-1)/W1528A were constructed by PCR mutagenesis with primers containing base alterations according to the previously described method [62]. To construct pCX4pur/myc-Cardif, the DNA fragment encoding Cardif (IPS-1/MAVS/VISA, accession no. DQ181928) was amplified from cDNAs obtained from PH5CH8 cells by PCR using KOD-plus DNA polymerase (Toyobo, Osaka, Japan). The primer sequences containing the *SphI* (forward) and *NotI* (reverse) recognition sites for Cardif were designed to enable expression of the Cardif ORF. The obtained DNA fragment was subcloned into the *SphI* and *NotI* sites of pCX4pur/myc, which can express myc-tagged protein, according to the previously described method [39]. To construct pCX4pur/myc-TRIF, the *EcoRI*-*NotI* fragment of pCXpur/myc-TRIF encoding myc-TRIF ORF [39] was subcloned into the *EcoRI* and *NotI* sites of pCX4pur. To construct pEGFP-C1/IRF-3, the DNA fragment encoding IRF-3 (accession no. NM_001571) was amplified by PCR as described above. The primer sequences containing the *XhoI* (forward) and *HindIII* (reverse) recognition sites for IRF-3 were designed to enable expression of the IRF-3 ORF. The obtained DNA fragment was subcloned into the *XhoI* and *HindIII* sites of pEGFP-C1 (Clontech, Mountain View, CA, USA), and the obtained pEGFP-C1/IRF-3 was used for IRF-3 dimerization analysis. The nucleotide sequences of these constructed expression vectors were confirmed by Big Dye termination cycle sequencing using an ABI Prism 310 genetic analyzer (Applied Biosystems, Foster City, CA, USA).

Poly(I-C) treatment

Poly(I-C) (GE Healthcare Bio-Sciences Corp., Piscataway, NJ, USA) was added to the medium at $50 \mu\text{g}\cdot\text{mL}^{-1}$ (M-pIC), or $1 \mu\text{g}$ of poly(I-C) was complexed with LipofectamineTM 2000 (Invitrogen) for transfection (T-pIC). Cells were assayed for poly(I-C)-induced responses 6 h after exposure by either route.

Luciferase reporter assay

For the dual luciferase assay, we used a firefly luciferase reporter vector, pIFN- β -(-125)-Luc [63], containing the IFN- β gene promoter region (-125 to +19). The reporter assay was carried out as previously described [40]. Briefly, a total of 0.3×10^5 cells were seeded in a 24-well plate, 24 h before transfection. Then, 0.1 μ g firefly luciferase reporter vector, 0.2–0.4 μ g HCV protein expression plasmid (pCX4bsr series), and 0.2 ng pRL-CMV (Promega, Madison, WI, USA) as an internal control reporter were transfected into the various cell lines. To maintain the efficiency of transfection, up to 0.4 μ g of pCX4bsr was added instead of HCV protein expression vectors. In some cases, 20 ng of pCX4pur/myc-Cardif or pCX4pur/myc-TRIF were added as the effector plasmid. The cells were cultured for 48 h, and then a dual luciferase assay was performed according to the manufacturer's protocol (Promega). In some cases, the cells were cultured for 42 h and then poly(I-C) was added to the medium or transfected into the cells for 6 h before the reporter assay. Three independent triplicate transfection experiments were conducted to verify the reproducibility of the results. Relative luciferase activity was normalized to the activity of *Renilla* luciferase (internal control). A manual Lumat LB 9501/16 luminometer (EG & G Berthold, Bad Wildbad, Germany) was used to detect luciferase activity.

Western blot analysis

Preparation of cell lysates, SDS/PAGE, and immunoblotting were performed as described previously [64]. Anti-NS3 (Novocastra Laboratories, Newcastle, UK), anti-myc (PL14; Medical and Biological Laboratories, Nagoya, Japan) or anti- β -actin serum (AC-15; Sigma, St Louis, MO, USA) was used in this study as a primary antibody. Immunocomplexes were detected by a Renaissance enhanced chemiluminescence assay (Perkin-Elmer Life Sciences, Boston, MA, USA).

IRF-3 dimerization analysis

Preparation of cell lysates and native-polyacrylamide gel electrophoresis were performed as described previously [65]. After the separation of proteins, immunoblotting was performed as described above. Anti-IRF3 serum (FL-425; Santa Cruz Biotechnology, Santa Cruz, CA, USA) was used for the detection of the endogenous IRF-3 dimerization. Anti-phospho-IRF-3 (Ser386) serum (IBL, Gunma, Japan) and anti-phospho-IRF-3 (Ser396) serum (Upstate Biotechnology, Lake Placid, NY, USA) were used for detection of the phosphorylated IRF-3. The dimerization of exogenous IRF-3 was detected by anti-EGFP monoclonal serum (JL-8; Clontech).

Preparation of PH5CH8 cells stably expressing HCV proteins

PH5CH8 cells were infected with retrovirus pCX4bsr encoding various HCV proteins, as described previously [64]. pCX4bsr/NS3-4A(1B-1), pCX4bsr/NS3-4A(1B-1)/S1165A, and pCX4bsr/NS3-4A(1B-1)/W1528A were used to obtain the PH5CH8 cells stably expressing NS3-4A(1B-1), the NS3-4A(1B-1)/S1165A mutant lacking the serine protease activity [51], and the NS3-4A(1B-1)/W1528A mutant lacking the helicase activity [66], respectively. At 2 days postinfection, PH5CH8 cells were changed with fresh medium containing blasticidin ($20 \mu\text{g}\cdot\text{mL}^{-1}$), and the culture was continued for 7 days to select the cells expressing HCV proteins.

Real-time LightCycler PCR

Total cellular RNA was extracted using an Isogen extraction kit (Nippon Gene, Toyama, Japan). Before reverse transcription, the RNA was treated with RNase-free DNase I (TaKaRa Bio, Ohtsu, Japan) to completely remove the genomic DNA as described previously [40]. Real-time LightCycler PCR was performed according to a method described previously [67]. The sequences of sense and antisense primers for TRIF (accession no. AB093555) were 5'-AAGCCATGATGAGCAACCTC-3' and 5'-GTGTCC TGTTCCCTCCTCCAC-3'. The sequences of sense and antisense primers for RIG-I (accession no. NM_014314) were 5'-AATGAAAGATGCTCTGGATTACTTG-3' and 5'-TTGTCTCTGGGTTAAGTGGTACTC-3'. The sequences of sense and antisense primers for MDA5 (accession no. NM_022168) were 5'-AAGTCATTAGTAAA TTTCGCACTGG-3' and 5'-TCATCTTCTCTCGGAAAT CATTAAAC-3'. In addition, we used primer sets for IFN- β [40], TLR3 [39], TLR4 [39], Cardif [24] and GAPDH [40].

RNA interference

siRNA duplexes targeting the coding regions of human TLR3 [39], TLR4 (Dharmacon, Lafayette, CO, USA; catalog no. M-008088-00), TRIF (Dharmacon; catalog no. M-012833-00), and luciferase GL2 [68] (Dharmacon) as a control were chemically synthesized. PH5CH8 cells were transfected with the indicated siRNA duplex using OligofectAMINE (Invitrogen). Total RNA was extracted at 3 days after transfection, and real-time LightCycler PCR was performed to examine RNA-mediated interference efficiency as described above.

Acknowledgements

We are grateful to Dr Tsuyoshi Akagi (Osaka Bioscience Institute) for providing the pCX4bsr and

pCX4pur vectors. We thank Toshiko Maeta and Takashi Nakamura for their technical assistance. Drs Kazuhito Naka (Kanazawa University) and Yasuo Ariumi (Okayama University) are also thanked for their valuable input in this study. This work was supported by Grants-in-Aid for the Third-Term Comprehensive 10-Year Strategy for Cancer Control, and by a Grant-in-Aid for Research on Hepatitis, both from the Ministry of Health, Labor, and Welfare of Japan.

References

- Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW & Houghton M (1989) Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. *Science* **244**, 359–362.
- Kuo G, Choo QL, Alter HJ, Gitnick GL, Redeker AG, Purcell RH, Miyamura T, Dienstag JL, Alter MJ, Stevens CE, Tegtmeier GE, Bonino F, Colombo WS, Lee WS, Kuo C, Berger K, Shuster JR, Overby LR, Bradley DW & Houghton M (1989) An assay for circulating antibodies to a major etiologic virus of human non-A, non-B hepatitis. *Science* **244**, 362–364.
- Ohkoshi S, Kojima H, Tawaraya H, Miyajima T, Kamimura T, Asakura H, Satoh A, Hirose S, Hijikata M, Kato N & Shimotohno K (1990) Prevalence of antibody against non-A, non-B hepatitis virus in Japanese patients with hepatocellular carcinoma. *Jpn J Cancer Res* **81**, 550–553.
- Saito I, Miyamura T, Ohbayashi A, Harada H, Katayama T, Kikuchi Y, Watanabe S, Koi S, Onji M, Ohta Y, Choo QL, Houghton M & Kuo G (1990) Hepatitis C virus infection is associated with the development of hepatocellular carcinoma. *Proc Natl Acad Sci USA* **87**, 6547–6549.
- Thomas DL (2000) Hepatitis C epidemiology. *Curr Top Microbiol Immunol* **242**, 25–41.
- Kato N, Hijikata M, Ootsuyama Y, Nakagawa M, Ohkoshi S, Sugiyama T & Shimotohno K (1990) Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. *Proc Natl Acad Sci USA* **87**, 9524–9528.
- Tanaka T, Kato N, Cho MJ & Shimotohno K (1995) A novel sequence found at the 3' terminus of hepatitis C virus genome. *Biochem Biophys Res Commun* **215**, 744–749.
- Hijikata M, Kato N, Ootsuyama Y, Nakagawa M & Shimotohno K (1991) Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis. *Proc Natl Acad Sci USA* **88**, 5547–5551.
- Hijikata M, Mizushima H, Tanji Y, Komada Y, Hirowatari Y, Akagi T, Kato N, Kimura K & Shimotohno K (1993) Proteolytic processing and membrane association of putative nonstructural proteins of hepatitis C virus. *Proc Natl Acad Sci USA* **90**, 10773–10777.
- Kato N (2001) Molecular virology of hepatitis C virus. *Acta Med Okayama* **55**, 133–159.
- Kawai T & Akira S (2006) Innate immune recognition of viral infection. *Nat Immunol* **7**, 131–137.
- Meylan E & Tschopp J (2006) Toll-like receptors and RNA helicases: two parallel ways to trigger antiviral responses. *Mol Cell* **22**, 561–569.
- Alexopoulou L, Holt AC, Medzhitov R & Flavell RA (2001) Recognition of double-stranded RNA and activation of NF-kappaB by Toll-like receptor 3. *Nature* **413**, 732–738.
- Honda K & Taniguchi T (2006) IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. *Nat Rev Immunol* **6**, 644–658.
- Kang DC, Gopalkrishnan RV, Wu Q, Jankowsky E, Pyle AM & Fisher PB (2002) mda-5: an interferon-inducible putative RNA helicase with double-stranded RNA-dependent ATPase activity and melanoma growth-suppressive properties. *Proc Natl Acad Sci USA* **99**, 637–642.
- Yoneyama M, Kikuchi M, Natsukawa T, Shinobu N, Imaizumi T, Miyagishi M, Taira K, Akira S & Fujita T (2004) The RNA helicase RIG-I has an essential function in double-stranded RNA-induced innate antiviral responses. *Nat Immunol* **5**, 730–737.
- Yoneyama M, Kikuchi M, Matsumoto K, Imaizumi T, Miyagishi M, Taira K, Foy E, Loo YM, Gale M Jr, Akira S, Yonehara S, Kato A & Fujita T (2005) Shared and unique functions of the DExD/H-box helicases RIG-I, MDA5, and LGP2 in antiviral innate immunity. *J Immunol* **175**, 2851–2858.
- Kato H, Takeuchi O, Sato S, Yoneyama M, Yamamoto M, Matsui K, Uematsu S, Jung A, Kawai T, Ishii KJ, Yamaguchi O, Otsu K, Tsujimura T, Koh CS, Reis e Sousa C, Matsuura Y, Fujita T & Akira S (2006) Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. *Nature* **441**, 101–105.
- Hornung V, Ellegast J, Kim S, Brzozka K, Jung A, Kato H, Poeck H, Akira S, Conzelmann KK, Schlee M, Endres S & Hartmann G (2006) 5'-Triphosphate RNA is the ligand for RIG-I. *Science* **314**, 994–997.
- Pichlmair A, Schulz O, Tan CP, Naslund TI, Liljestrom P, Weber F & Reis e Sousa C (2006) RIG-I-mediated antiviral responses to single-stranded RNA bearing 5'-phosphates. *Science* **314**, 997–1001.
- Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K & Akira S (2002) Cutting edge: a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta promoter in the Toll-like receptor signaling. *J Immunol* **169**, 6668–6672.

- 22 Yamamoto M, Sato S, Hemmi H, Hoshino K, Kaisho T, Sanjo H, Takeuchi O, Sugiyama M, Okabe M, Takeda K & Akira S (2003) Role of adaptor TRIF in the MyD88-independent toll-like receptor signaling pathway. *Science* **301**, 640–643.
- 23 Oshiumi H, Matsumoto M, Funami K, Akazawa T & Seya T (2003) TICAM-1, an adaptor molecule that participates in Toll-like receptor 3-mediated interferon-beta induction. *Nat Immunol* **4**, 161–167.
- 24 Meylan E, Curran J, Hofman K, Moradpour D, Binder M, Bartenschlager R & Tschopp J (2005) Cardif is an adaptor protein in the RIG-I antiviral pathway and is targeted by hepatitis C virus. *Nature* **437**, 1167–1172.
- 25 Kawai T, Takahashi K, Sato S, Coban C, Kumar H, Kato H, Ishii KJ, Takeuchi O & Akira S (2005) IPS-1, an adaptor triggering RIG-I- and Mda5-mediated type I interferon induction. *Nat Immunol* **6**, 981–988.
- 26 Seth RB, Sun L, Ea CK & Chen ZJ (2005) Identification and characterization of MAVS, a mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. *Cell* **122**, 669–682.
- 27 Xu LG, Wang YY, Han KJ, Li LY, Zhai Z & Shu HB (2005) VISA is an adapter protein required for virus-triggered IFN-beta signaling. *Mol Cell* **19**, 727–740.
- 28 Yoneyama M, Suhara W, Fukuhara Y, Fukada M, Nishida E & Fujita T (1998) Direct triggering of the type I interferon system by virus infection: activation of a transcription factor complex containing IRF-3 and CBP/p300. *EMBO J* **17**, 1087–1095.
- 29 Lin R, Heylbroeck C, Pitha PM & Hiscott J (1998) Virus-dependent phosphorylation of the IRF-3 transcription factor regulates nuclear translocation, transactivation potential, and proteasome-mediated degradation. *Mol Cell Biol* **18**, 2986–2996.
- 30 Sharma S, tenOever BR, Grandvaux N, Zhou GP, Lin R & Hiscott J (2003) Triggering the interferon antiviral response through an IKK-related pathway. *Science* **300**, 1148–1151.
- 31 Fitzgerald KA, McWhirter SM, Faia KL, Rowe DC, Latz E, Golenbock DT, Coyle AJ, Liao SM & Maniatis T (2003) IKKepsilon and TBK1 are essential components of the IRF3 signaling pathway. *Nat Immunol* **4**, 491–496.
- 32 Talon J, Horvath CM, Polley R, Basler CF, Muster T, Palese P & Garcia-Sastre A (2000) Activation of interferon regulatory factor 3 is inhibited by the influenza A virus NS1 protein. *J Virol* **74**, 7989–7996.
- 33 Foy E, Li K, Wang C, Sumpter R Jr, Ikeda M, Lemon SM & Gale M Jr (2003) Regulation of interferon regulatory factor-3 by the hepatitis C virus serine protease. *Science* **300**, 1145–1148.
- 34 Li XD, Sun L, Seth RB, Pineda G & Chen ZJ (2005) Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. *Proc Natl Acad Sci USA* **102**, 17717–17722.
- 35 Foy E, Li K, Sumpter R Jr, Loo YM, Johnson CL, Wang C, Fish PM, Yoneyama M, Fujita T, Lemon SM & Gale M Jr (2005) Control of antiviral defenses through hepatitis C virus disruption of retinoic acid-inducible gene-I signaling. *Proc Natl Acad Sci USA* **102**, 2986–2991.
- 36 Li K, Foy E, Ferreone JC, Nakamura M, Ferreone AC, Ikeda M, Ray SC, Gale M Jr & Lemon SM (2005) Immune evasion by hepatitis C virus NS3/4A protease-mediated cleavage of the Toll-like receptor 3 adaptor protein TRIF. *Proc Natl Acad Sci USA* **102**, 2992–2997.
- 37 Otsuka M, Kato N, Moriyama M, Taniguchi H, Wang Y, Dharel N, Kawabe T & Omata M (2005) Interaction between the HCV NS3 protein and the host TBK1 protein leads to inhibition of cellular antiviral responses. *Hepatology* **41**, 1004–1012.
- 38 Breiman A, Grandvaux N, Lin R, Ottone C, Akira S, Yoneyama M, Fujita T, Hiscott J & Meurs EF (2005) Inhibition of RIG-I-dependent signaling to the interferon pathway during hepatitis C virus expression and restoration of signaling by IKKepsilon. *J Virol* **79**, 3969–3977.
- 39 Naka K, Dansako H, Kobayashi N, Ikeda M & Kato N (2005) Hepatitis C virus NS5B delays cell cycle progression by inducing interferon-beta via Toll-like receptor 3 signaling pathway without replicating viral genomes. *Virology* **346**, 348–362.
- 40 Dansako H, Naka K, Ikeda M & Kato N (2005) Hepatitis C virus proteins exhibit conflicting effects on the interferon system in human hepatocyte cells. *Biochem Biophys Res Commun* **336**, 458–468.
- 41 Li K, Chen Z, Kato N, Gale M Jr & Lemon SM (2005) Distinct poly(I-C) and virus-activated signaling pathways leading to interferon-beta production in hepatocytes. *J Biol Chem* **280**, 16739–16747.
- 42 Lanford RE, Guerra B, Lee H, Averett DR, Pfeiffer B, Chavez D, Notvall L & Bigger C (2003) Antiviral effect and virus-host interactions in response to alpha interferon, gamma interferon, poly(i)-poly(c), tumor necrosis factor alpha, and ribavirin in hepatitis C virus subgenomic replicons. *J Virol* **77**, 1092–1104.
- 43 Ikeda M, Abe K, Dansako H, Nakamura T, Naka K & Kato N (2005) Efficient replication of a full-length hepatitis C virus genome, strain O, in cell culture, and development of a luciferase reporter system. *Biochem Biophys Res Commun* **329**, 1350–1359.
- 44 Naka K, Ikeda M, Abe K, Dansako H & Kato N (2005) Mizoribine inhibits hepatitis C virus RNA replication: effect of combination with interferon-alpha. *Biochem Biophys Res Commun* **330**, 871–879.
- 45 Ikeda M, Sugiyama K, Mizutani T, Tanaka T, Tanaka K, Sekihara H, Shimotohno K & Kato N (1998) Human hepatocyte clonal cell lines that support persist-

- ent replication of hepatitis C virus. *Virus Res* **56**, 157–167.
- 46 Kawai T, Takeuchi O, Fujita T, Inoue J, Muhlradt PF, Sato S, Hoshino K & Akira S (2001) Lipopolysaccharide stimulates the MyD88-independent pathway and results in activation of IFN-regulatory factor 3 and the expression of a subset of lipopolysaccharide-inducible genes. *J Immunol* **167**, 5887–5894.
 - 47 Doyle S, Vaidya S, O'Connell R, Dadgostar H, Dempsey P, Wu T, Rao G, Sun R, Haberland M, Modlin R & Cheng G (2002) IRF3 mediates a TLR3/TLR4-specific antiviral gene program. *Immunity* **17**, 251–263.
 - 48 Li XD, Sun L, Seth RB, Pineda G & Chen ZJ (2005) Hepatitis C virus protease NS3/4A cleaves mitochondrial antiviral signaling protein off the mitochondria to evade innate immunity. *Proc Natl Acad Sci USA* **102**, 17717–17722.
 - 49 Lin R, Lacoste J, Nakhaei P, Sun Q, Yang L, Paz S, Wilkinson P, Julkunen I, Vitour D, Meurs E & Hiscott J (2006) Dissociation of a MAVS/IPS-1/VISA/Cardif-IKepsilon molecular complex from the mitochondrial outer membrane by hepatitis C virus NS3-4A proteolytic cleavage. *J Virol* **80**, 6072–6083.
 - 50 Loo YM, Owen DM, Li K, Erickson AK, Johnson CL, Fish PM, Carney DS, Wang T, Ishida H, Yoneyama M, Fujita T, Saito T, Lee WM, Hagedorn CH, Lau DT, Weinman SA, Lemon SM & Gale M Jr (2006) Viral and therapeutic control of IFN-beta promoter stimulator 1 during hepatitis C virus infection. *Proc Natl Acad Sci USA* **103**, 6001–6006.
 - 51 Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K & Shimotohno K (1993) Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. *J Virol* **67**, 4665–4675.
 - 52 Kobayashi N, Fujiwara T, Westerman KA, Inoue Y, Sakaguchi M, Noguchi H, Miyazaki M, Cai J, Tanaka N, Fox IJ & LeBoulch P (2000) Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. *Science* **287**, 1258–1262.
 - 53 Nguyen TH, Mai G, Villiger P, Oberholzer J, Salmon P, Morel P, Buhler L & Trono D (2005) Treatment of acetaminophen-induced acute liver failure in the mouse with conditionally immortalized human hepatocytes. *J Hepatol* **43**, 1031–1037.
 - 54 Nomura-Takigawa Y, Nagano-Fujii M, Deng L, Kitazawa S, Ishido S, Sada K & Hotta H (2006) Non-structural protein 4A of hepatitis C virus accumulates on mitochondria and renders the cells prone to undergoing mitochondria-mediated apoptosis. *J Gen Virol* **87**, 1935–1945.
 - 55 De Francesco R & Steinkuhler C (2000) Structure and function of the hepatitis C virus NS3-NS4A serine proteinase. *Curr Top Microbiol Immunol* **242**, 149–169.
 - 56 Cheng G, Zhong J & Chisari FV (2006) Inhibition of dsRNA-induced signaling in hepatitis C virus-infected cells by NS3 protease-dependent and -independent mechanisms. *Proc Natl Acad Sci USA* **103**, 8499–8504.
 - 57 Ikeda M, Kato N, Mizutani T, Sugiyama K, Tanaka K & Shimotohno K (1997) Analysis of the cell tropism of HCV by using in vitro HCV-infected human lymphocytes and hepatocytes. *J Hepatol* **27**, 445–454.
 - 58 Noguchi M & Hirohashi S (1996) Cell lines from non-neoplastic liver and hepatocellular carcinoma tissue from a single patient. *In Vitro Cell Dev Biol Anim* **32**, 135–137.
 - 59 Akagi T, Sasai K & Hanafusa H (2003) Refractory nature of normal human diploid fibroblasts with respect to oncogene-mediated transformation. *Proc Natl Acad Sci USA* **100**, 13567–13572.
 - 60 Naganuma A, Nozaki A, Tanaka T, Sugiyama K, Takagi H, Mori M, Shimotohno K & Kato N (2000) Activation of the interferon-inducible 2'-5'-oligoadenylate synthetase gene by hepatitis C virus core protein. *J Virol* **74**, 8744–8750.
 - 61 Sugiyama K, Kato N, Mizutani T, Ikeda M, Tanaka T & Shimotohno K (1997) Genetic analysis of the hepatitis C virus (HCV) genome from HCV-infected human T cells. *J Gen Virol* **78**, 329–336.
 - 62 Dansako H, Naganuma A, Nakamura T, Ikeda F, Nozaki A & Kato N (2003) Differential activation of interferon-inducible genes by hepatitis C virus core protein mediated by the interferon stimulated response element. *Virus Res* **97**, 17–30.
 - 63 Benesch P, Vigneron M, Peretz D, Revel M & Chebath J (1987) Interferon-responsive regulatory elements in the promoter of the human 2',5'-oligo(A) synthetase gene. *Mol Cell Biol* **7**, 4498–4504.
 - 64 Naganuma A, Dansako H, Nakamura T, Nozaki A & Kato N (2004) Promotion of microsatellite instability by hepatitis C virus core protein in human non-neoplastic hepatocyte cells. *Cancer Res* **64**, 1307–1314.
 - 65 Iwamura T, Yoneyama M, Yamaguchi K, Suhara W, Mori W, Shiota K, Okabe Y, Namiki H & Fujita T (2001) Induction of IRF-3/-7 kinase and NF-kappaB in response to double-stranded RNA and virus infection: common and unique pathways. *Genes Cells* **6**, 375–388.
 - 66 Tai CL, Pan WC, Liaw SH, Yang UC, Hwang LH & Chen DS (2001) Structure-based mutational analysis of the hepatitis C virus NS3 helicase. *J Virol* **75**, 8289–8297.
 - 67 Abe K, Ikeda M, Dansako H, Naka K, Shimotohno K & Kato N (2005) cDNA microarray analysis to compare HCV subgenomic replicon cells with their cured cells. *Virus Res* **107**, 73–81.
 - 68 Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K & Tuschl T (2001) Duplexes of 21-nucleotide

RNAs mediate RNA interference in cultured mammalian cells. *Nature* **411**, 494–498.

Supplementary material

The following supplementary material is available online:

Fig. S1. NS3-4A blocked the Cardif-mediated signaling pathway, but not the TRIF-mediated signaling pathway in HeLa cells.

Fig. S2. NS3-4A is capable of cleaving Cardif, but not TRIF in HeLa cells.

Table S1. Quantitative RT-PCR analysis of mRNA expression of several factors involving in innate immune response in the various cell lines.

This material is available as part of the online article from <http://www.blackwell-synergy.com>

Please note: Blackwell Publishing is not responsible for the content or functionality of any supplementary materials supplied by the authors. Any queries (other than missing material) should be directed to the corresponding author for the article.